CAJ | 학술논문

基于各项Ⅲ期临床研究,近年来,术后化放疗、围手术期ECF方案(表柔比星、顺铂和氟尿嘧啶)化疗以及术后口服S-1辅助化疗分别成为了美国、欧洲和日本治疗可切除性胃癌的标准辅助治疗方式.2001年,美国西南肿瘤组(SWOG)报道的大型Ⅲ期随机临床试验(INT0116)结果,使得术后化放疗在美国成为可切除性胃癌的标准治疗方式.随着化放疗技术的快速发展,术前化放疗、术后化放疗、化放疗联合术中放疗等各种化放疗方案不断地被业内学者所报道.本综述总结近年来报道的关于胃癌患者手术前后的辅助性化放疗方案及其临床试验结果,并综合评价化放疗在可切除性胃癌中的治疗价值及意义.
기우각항Ⅲ기림상연구,근년래,술후화방료、위수술기ECF방안(표유비성、순박화불뇨밀정)화료이급술후구복S-1보조화료분별성위료미국、구주화일본치료가절제성위암적표준보조치료방식.2001년,미국서남종류조(SWOG)보도적대형Ⅲ기수궤림상시험(INT0116)결과,사득술후화방료재미국성위가절제성위암적표준치료방식.수착화방료기술적쾌속발전,술전화방료、술후화방료、화방료연합술중방료등각충화방료방안불단지피업내학자소보도.본종술총결근년래보도적관우위암환자수술전후적보조성화방료방안급기림상시험결과,병종합평개화방료재가절제성위암중적치료개치급의의.
In recent years,based on the phase Ⅲ clinical study, postoperative chemoradiation, perioperative chemotherapy with ECF regimen and postoperative adjuvant chemotherapy with oral S-1 have become the standard adjuvant treatment of resectable gastric adenocarcinoma in the United States,Europe,and Japan,respectively.Since the Southwest Oncology Group in 2001 reported a large phase Ⅲ randomized clinical trial INT0116,adjuvant chemoradiotherapy has become a standard treatment for gastric adenocarcinoma.With the rapid development of chemoradiotherapy technique,clinical researches for using operation combined with chemoradiotherapy to treat gastric adenocarcinoma emerged one after another,including adjuvant postoperative chemoradiation,preoperative chemoradiation, and chemoradiation combined with intraoperative radiotherapy and so on.This review will summarize the recent treatment protocol using chemoradiotherapy for resectable gastric adenocarcinoma,and comprehensively evaluate the clinical value and significance of chemoradiotherapy for resectable gastric adenocarcinoma.